People aged 18 and older with an eye condition called ABCA4 retinopathy may consider participating in a clinical trial seeking to determine if the study drug is safe for individuals with Stargardt disease, the most common form of this condition. This disease, caused by mutations in a gene known as ABCA4, damages the retina, the part of the back of the eye that detects light. Its effects lead to vision loss. The STELLAR research study may also help scientists understand the potential of ACDN-01 to slow the progress or stop retina damage for those with Stargardt disease and other retinopathies. For eligible study participants and their care partners, travel will be provided for study-related assessments. To determine if participation in this study is appropriate, potential participants are asked to speak with their ophthalmologist or with a doctor at one of the ten study locations across the U.S. To learn more, visit the webpage describing the STELLAR Clinical Trial.
Menu
